Annual Total Long Term Liabilities
$504.57 M
+$25.16 M+5.25%
December 31, 2023
Summary
- As of February 25, 2025, ESPR annual total long term liabilities is $504.57 million, with the most recent change of +$25.16 million (+5.25%) on December 31, 2023.
- During the last 3 years, ESPR annual total long term liabilities has risen by +$149.24 million (+42.00%).
- ESPR annual total long term liabilities is now -0.12% below its all-time high of $505.18 million, reached on December 31, 2021.
Performance
ESPR Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$518.45 M
-$2.75 M-0.53%
September 30, 2024
Summary
- As of February 25, 2025, ESPR quarterly total long term liabilities is $518.45 million, with the most recent change of -$2.75 million (-0.53%) on September 30, 2024.
- Over the past year, ESPR quarterly long term liabilities has stayed the same.
- ESPR quarterly long term liabilities is now -1.17% below its all-time high of $524.58 million, reached on September 30, 2022.
Performance
ESPR Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
ESPR Long Term Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +5.3% | 0.0% |
| 3 y3 years | +42.0% | 0.0% |
| 5 y5 years | +100.0% | +301.1% |
ESPR Long Term Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -0.1% | +5.3% | -1.2% | +8.1% |
| 5 y | 5-year | -0.1% | +292.9% | -1.2% | +303.7% |
| alltime | all time | -0.1% | -100.0% | -1.2% | -100.0% |
Esperion Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $518.45 M(-0.5%) |
| Jun 2024 | - | $521.20 M(+3.7%) |
| Mar 2024 | - | $502.85 M(-0.3%) |
| Dec 2023 | $504.57 M(+5.2%) | $504.57 M(+2.2%) |
| Sep 2023 | - | $493.60 M(-1.2%) |
| Jun 2023 | - | $499.43 M(+2.8%) |
| Mar 2023 | - | $486.00 M(+1.4%) |
| Dec 2022 | $479.41 M(-5.1%) | $479.41 M(-8.6%) |
| Sep 2022 | - | $524.58 M(+2.2%) |
| Jun 2022 | - | $513.40 M(+0.1%) |
| Mar 2022 | - | $512.81 M(+1.5%) |
| Dec 2021 | $505.18 M(+42.2%) | $505.18 M(-0.8%) |
| Sep 2021 | - | $509.48 M(+1.5%) |
| Jun 2021 | - | $502.13 M(+11.6%) |
| Mar 2021 | - | $450.11 M(+26.7%) |
| Dec 2020 | $355.32 M(+176.7%) | $355.32 M(+114.0%) |
| Sep 2020 | - | $166.06 M(+3.2%) |
| Jun 2020 | - | $160.98 M(+2.9%) |
| Mar 2020 | - | $156.44 M(+21.8%) |
| Dec 2019 | $128.42 M(>+9900.0%) | $128.42 M(-0.6%) |
| Sep 2019 | - | $129.24 M(+3.3%) |
| Jun 2019 | - | $125.17 M(+8550.2%) |
| Mar 2019 | - | $1.45 M(>+9900.0%) |
| Dec 2018 | $0.00 | $0.00(0.0%) |
| Sep 2018 | - | $0.00(0.0%) |
| Jun 2018 | - | $0.00(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2018 | - | $0.00(0.0%) |
| Dec 2017 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2017 | - | $0.00(-100.0%) |
| Jun 2017 | - | $140.00 K(-76.1%) |
| Mar 2017 | - | $585.00 K(-42.8%) |
| Dec 2016 | $1.02 M(-62.0%) | $1.02 M(-29.6%) |
| Sep 2016 | - | $1.45 M(-22.4%) |
| Jun 2016 | - | $1.87 M(-18.0%) |
| Mar 2016 | - | $2.28 M(-15.1%) |
| Dec 2015 | $2.69 M(-36.5%) | $2.69 M(-12.8%) |
| Sep 2015 | - | $3.08 M(-11.2%) |
| Jun 2015 | - | $3.47 M(-9.9%) |
| Mar 2015 | - | $3.85 M(-8.9%) |
| Dec 2014 | $4.23 M(>+9900.0%) | $4.23 M(-9.5%) |
| Sep 2014 | - | $4.68 M(-5.0%) |
| Jun 2014 | - | $4.92 M(>+9900.0%) |
| Mar 2014 | - | $0.00(0.0%) |
| Dec 2013 | $0.00(-100.0%) | $0.00(0.0%) |
| Sep 2013 | - | $0.00(0.0%) |
| Jun 2013 | - | $0.00(0.0%) |
| Mar 2013 | - | $0.00(-100.0%) |
| Dec 2012 | $7.53 M(+9.2%) | $7.53 M |
| Dec 2011 | $6.90 M(-10.8%) | - |
| Dec 2002 | $7.73 M(+41.0%) | - |
| Dec 2001 | $5.48 M(+81.1%) | - |
| Dec 2000 | $3.03 M(+32.5%) | - |
| Dec 1999 | $2.28 M | - |
FAQ
- What is Esperion Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Esperion Therapeutics?
- What is Esperion Therapeutics annual total long term liabilities year-on-year change?
- What is Esperion Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Esperion Therapeutics?
- What is Esperion Therapeutics quarterly long term liabilities year-on-year change?
What is Esperion Therapeutics annual total long term liabilities?
The current annual total long term liabilities of ESPR is $504.57 M
What is the all time high annual total long term liabilities for Esperion Therapeutics?
Esperion Therapeutics all-time high annual total long term liabilities is $505.18 M
What is Esperion Therapeutics annual total long term liabilities year-on-year change?
Over the past year, ESPR annual total long term liabilities has changed by +$25.16 M (+5.25%)
What is Esperion Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of ESPR is $518.45 M
What is the all time high quarterly long term liabilities for Esperion Therapeutics?
Esperion Therapeutics all-time high quarterly total long term liabilities is $524.58 M
What is Esperion Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, ESPR quarterly total long term liabilities has changed by $0.00 (0.00%)